Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2012 | 02:00pm CEST

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news
Date Title
10:03a SAVOLA : announces the appointment of the Chairman of the Board and form the new Board's committees for the new office term
09:53a GITI TIRE : to Com
09:50a BRIEF : Featured pets
09:49a TRANSCANADA : files suit against US over Keystone XL pipeline
09:07a HONDA MOTOR : BC-CAR--IndyCar-Road America Lineup
09:07a BOJANGLES : Journal West calendar
09:02a BLUEBIRD BIO : Diana Colleluori at Bluebird Bio to Present at GTCbio’s Cell & Gene Therapy Conference
09:02a MICROSOFT : HostForLIFE.eu Proudly Launches Drupal 8.1.2 Hosting
09:02a RENTOKIL INITIAL : Malaysia Reveals Vital Importance of Proactive Bed Bug Management in Hotels to Prevent Future Infestations
09:02a INTEL : Spintelligent Marks Half-Year with Record After Record at Its African Events
Latest news
Advertisement
Hot News 
ELECTRO RENT : Platinum Equity Increases Electro Rent Purchase Price Offer to $15.50 Per Share
Incipio Group to Acquire Skullcandy; Create Leading Technology, Creative Culture and Mobile Lifestyle Company
FINISH LINE : Reports First Quarter Fiscal Year 2017 Results
LSL PROPERTY SERVICES : May 16 Buy-to-Let Index
B&M EUROPEAN VALUE RETAIL : Annual Report and Accounts 2016
Most Read News
06/25 Russia secures energy deals, talks security with China as Putin visits
01:01a VOLKSWAGEN SHOULD PAY EUROPEANS SAME COMPENSATION AS U.S. DRIVERS : EU commissioner
06/25 Expanded Panama Canal - Bigger ships, bigger paydays for beans, coal, gas
06/25 Alipay could take stake in Wirecard - report
06/25 MANCHESTER UNITED : close in on Henrikh Mkhitaryan and Zlatan Ibrahimovic deals
Most recommended articles
03:01a China's finance minister sees 'Brexit' heightening uncertainty for markets
01:42a VOLKSWAGEN : VW should pay Europeans same compensation as U.S. drivers - EU commissioner
06/25 Line, the biggest tech IPO of the year, struggles to show its growth plan can work
06/25 Chinese insurers run 'Titanic' risks for titanic returns
06/25 Expanded Panama Canal - Bigger ships, bigger paydays for beans, coal, gas